An FDA panel today advised the agency against requiring more large clinical studies for the cardiovascular risks of drugs that treat opioid-induced constipution, relieving drugmakers like AstraZeneca, Salix Pharmaceuticals and others from bearing the burden of further clinical safety trials.
written on 12.06.2014
FDA panel advises against more clinical trials for opioid constipation drugs
